PALVELLA THERAPEUTICS, INC. 8-K — AI Bull & Bear Analysis

The transition of PVLA from the Nasdaq Capital Market to the Nasdaq Global Market is a double-edged sword. While it technically elevates the company's prestige and institutional reach, it does not fundamentally alter the risk profile of its clinical pipeline or its cash runway. Investors must determine if this structural upgrade can be leveraged into a meaningful capital raise or if it simply adds administrative burden to a company still searching for its first commercial success.